Literature DB >> 3087328

Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture.

C Lewandowski, S Klug, H Nau, D Neubert.   

Abstract

Pharmacokinetic studies were performed in connection with culture experiments. Using the technique of cultivating whole rat embryos of the early postimplantation stage, we measured the concentration of valproic acid (VPA) and 2-en-VPA in the culture medium (free and protein-bound form) and in embryonic tissue. The following results were obtained: The concentrations of VPA and 2-en-VPA reached in the embryos were lower than corresponding total concentrations added to the culture medium, but exceeded the free concentrations in the medium. The concentrations of 2-en-VPA found in the embryo were lower than the comparable VPA total levels because of the more extensive protein binding of 2-en-VPA in the culture serum. The percentage of binding to serum proteins decreased with increasing total drug concentrations in the medium; the concentration of the free drug in the medium increased overproportionally with increasing total drug concentrations. Therefore, the free drug concentrations in the medium were not proportional to the dose of the drug dissolved in the medium (for a drug bound to plasma proteins). The concentrations of VPA and 2-en-VPA found in the embryos after incubation in vitro were not proportional to the drug concentrations dissolved in the medium. This result has to be taken into account when dose-response relationships are evaluated. VPA concentrations of 40 micrograms/g wet weight and above in the embryos clearly induced abnormal development in about 30% of the embryos, while 2-en-VPA concentrations as high as 200 micrograms/g embryo (wet weight) were inactive.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087328     DOI: 10.1007/bf00297113

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  13 in total

1.  Spina bifida and in-utero exposure to valproate.

Authors:  D Lindhout; H Meinardi
Journal:  Lancet       Date:  1984-08-18       Impact factor: 79.321

2.  Valproate and birth defects.

Authors:  E Robert; F Rosa
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

3.  Valproic acid and spina bifida.

Authors:  T Bjerkedal; A Czeizel; J Goujard; B Kallen; P Mastroiacova; N Nevin; G Oakley; E Robert
Journal:  Lancet       Date:  1982-11-13       Impact factor: 79.321

4.  Possible teratogenic effect of valproate during pregnancy.

Authors:  S Koch; E Jäger-Roman; D Rating; H Helge
Journal:  J Pediatr       Date:  1983-12       Impact factor: 4.406

5.  A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations.

Authors:  H Nau; R Zierer; H Spielmann; D Neubert; C Gansau
Journal:  Life Sci       Date:  1981-12-28       Impact factor: 5.037

6.  Anticonvulsant activity and embryotoxicity of valproic acid.

Authors:  H Nau; W Löscher; H Schäfer
Journal:  Neurology       Date:  1984-03       Impact factor: 9.910

7.  Microscale ultrafiltration technique for determining free drug in 50-microL serum samples.

Authors:  W Wittfoht; K Duwe; W Kuhnz; H Nau
Journal:  Clin Chem       Date:  1984-06       Impact factor: 8.327

8.  Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy.

Authors:  W Löscher; H Nau; C Marescaux; M Vergnes
Journal:  Eur J Pharmacol       Date:  1984-03-23       Impact factor: 4.432

9.  Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers.

Authors:  H Nau; D Rating; S Koch; I Häuser; H Helge
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

10.  Valproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissues by gas chromatography-mass spectrometry using selected ion monitoring.

Authors:  H Nau; W Wittfoht; H Schäfer; C Jakobs; D Rating; H Helge
Journal:  J Chromatogr       Date:  1981-11-13
View more
  8 in total

1.  Effects of valproic acid, some of its metabolites and analogues on prenatal development of rats in vitro and comparison with effects in vivo.

Authors:  S Klug; C Lewandowski; F Zappel; H J Merker; H Nau; D Neubert
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

2.  Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.

Authors:  R L Semmes; D D Shen
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

3.  Pharmacokinetics of total and free valproic acid during monotherapy in infants.

Authors:  L Herngren; B Lundberg; A Nergårdh
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

4.  Delta 2-valproate biotransformation using human liver microsomal fractions.

Authors:  G Fabre; C Briot; E Marti; J P Montseny; M Bourrié; D Massé; Y Berger; J P Cano
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 5.  Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as delta 2-valproate.

Authors:  H Nau; H Siemes
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 6.  Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in animals.

Authors:  W Löscher
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 7.  Influence of co-medication on the metabolism of valproate.

Authors:  F Pisani
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

8.  Species differences in pharmacokinetics and drug teratogenesis.

Authors:  H Nau
Journal:  Environ Health Perspect       Date:  1986-12       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.